Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$481.71 USD
+5.56 (1.17%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $481.72 +0.01 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
F Value F Growth B Momentum F VGM
Income Statements
Fiscal Year end for Vertex Pharmaceuticals Incorporated falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 9,869 | 8,931 | 7,574 | 6,206 | 4,163 |
Cost Of Goods | 1,262 | 1,080 | 904 | 736 | 548 |
Gross Profit | 8,607 | 7,850 | 6,670 | 5,469 | 3,615 |
Selling & Adminstrative & Depr. & Amort Expenses | 4,775 | 3,543 | 3,888 | 2,613 | 2,418 |
Income After Depreciation & Amortization | 3,832 | 4,307 | 2,782 | 2,856 | 1,198 |
Non-Operating Income | 592 | -20 | 10 | 319 | 256 |
Interest Expense | 44 | 55 | 62 | 58 | 59 |
Pretax Income | 4,380 | 4,232 | 2,730 | 3,117 | 1,395 |
Income Taxes | 760 | 910 | 388 | 405 | 218 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 3,620 | 3,322 | 2,342 | 2,712 | 1,177 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 3,620 | 3,322 | 2,342 | 2,712 | 1,177 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 4,013 | 4,456 | 2,908 | 2,966 | 1,305 |
Depreciation & Amortization (Cash Flow) | 181 | 148 | 126 | 110 | 107 |
Income After Depreciation & Amortization | 3,832 | 4,307 | 2,782 | 2,856 | 1,198 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 260.50 | 259.10 | 259.90 | 263.40 | 260.67 |
Diluted EPS Before Non-Recurring Items | 13.80 | 13.28 | 11.87 | 9.03 | 4.29 |
Diluted Net EPS (GAAP) | 13.89 | 12.82 | 9.01 | 10.29 | 4.51 |
Fiscal Year end for Vertex Pharmaceuticals Incorporated falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | NA | 2,645.60 | 2,690.60 | 2,517.70 | 2,483.50 |
Cost Of Goods | NA | 371.90 | 342.60 | 368.00 | 318.70 |
Gross Profit | NA | 2,273.70 | 2,348.00 | 2,149.70 | 2,164.80 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 5,788.40 | 1,208.50 | 1,161.20 | 1,126.70 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -3,514.70 | 1,139.50 | 988.50 | 1,038.10 |
Non-Operating Income | NA | 133.40 | 150.00 | 169.70 | 152.00 |
Interest Expense | NA | 9.90 | 10.40 | 10.60 | 10.90 |
Pretax Income | NA | -3,391.20 | 1,279.10 | 1,147.60 | 1,179.20 |
Income Taxes | NA | 202.40 | 179.50 | 178.80 | 143.90 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -3,593.60 | 1,099.60 | 968.80 | 1,035.30 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -3,593.60 | 1,099.60 | 968.80 | 1,035.30 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 258.10 | 261.10 | 260.90 | 260.50 |
Diluted EPS Before Non-Recurring Items | NA | -13.27 | 4.29 | 3.57 | 3.67 |
Diluted Net EPS (GAAP) | NA | -13.92 | 4.21 | 3.71 | 3.97 |